Latest Updates

News

Company news and research, regulatory and industry insights from Nikko Pharma Japan Co., Ltd.

  • Blood sample tubes in a rack in a clinical laboratory
    Cardiovascular Research

    Beyond LDL-C: Why apoB and Lp(a) Matter for Residual Cardiovascular Risk

    Recent ACC commentary highlights why apoB and Lp(a) can add important information beyond LDL cholesterol, helping clinicians assess cardiovascular risk more precisely.

  • Fresh turmeric root, turmeric powder and capsules on a laboratory bench
    Research & Safety

    Turmeric and Liver Health: Understanding the Latest Safety Evidence

    International safety alerts and a 2026 USP review put turmeric supplements in context: reassuring clinical-trial findings, rare liver-injury reports, and the importance of formulation-specific evidence and appropriate use.

  • Technician in protective clothing checking a bottle of tablets on a manufacturing line
    Regulatory Insights

    Japan’s FFC GMP Requirements Enter Full Implementation

    Japan’s updated manufacturing requirements for specified Foods with Function Claims took full effect in September 2026. The change places renewed emphasis on documented quality management, clear responsibilities and traceability throughout the relevant production supply chain.

  • Stage screen for The Metabolic Bloom, the PURO Fenōfitto launch on 15 August 2026 at Hyatt Regency Kuala Lumpur at KL Midtown
    Company News

    Nikko Pharma and A. Menarini Mark the PURO Fenōfitto Launch in Kuala Lumpur

    Nikko Pharma and partner distributor A. Menarini marked the PURO Fenōfitto launch at “The Metabolic Bloom” in Kuala Lumpur, with a scientific programme developed for healthcare professionals and focused on the research background of botanical ingredients.

  • Researcher pipetting into a cell culture plate beside a microscope
    Regenerative Medicine

    Japan Grants Conditional, Time-Limited Approval to Two iPSC Therapies

    Japan granted conditional, time-limited approval to RiHEART and AMCHEPRY in March 2026. The milestone advances iPSC-based regenerative medicine while underscoring the need for continued evaluation of efficacy and safety after approval in defined clinical settings.

  • Omega-3 softgel capsules in a glass dish beside an open journal and a stethoscope
    Clinical & Industry Insights

    2025 European Guidelines Clarify the Role of Prescription EPA

    The ESC/EAS lipid guideline update highlights a specific prescription EPA treatment for selected patients, reinforcing why evidence for cardiovascular medicines should not be generalized to fish-oil supplements.

  • Older couple walking together along a garden path
    Research Insights

    Omega-3 and Biological Ageing: What DO-HEALTH Measured

    A DO-HEALTH analysis reported modest changes in biological ageing biomarkers with omega-3 over three years. The findings offer a useful research signal, but do not demonstrate longer life or establish benefits for any commercial product.